Disruptive Technology ChannelGenomics Advancements Could Aid Breast Cancer PreventionBy Tom LydonAugust 4, 2021
Disruptive Technology ChannelUnpacking the Potential of the Synthetic Biology SpaceBy Tom LydonJuly 21, 2021
Disruptive Technology ChannelThe ARKG ETF and the Intersection of All Things TechBy Tom LydonJuly 13, 2021
Disruptive Technology ChannelPlay the New Era of Gene Editing with the ARKG ETFBy Tom LydonJuly 2, 2021
Disruptive Technology ChannelNew Gene Editing Trial Results Bump the ARKG ETFBy Tom LydonJune 29, 2021
Disruptive Technology ChannelBiogen Alzheimer’s Approval Could Signal FDA’s FlexibilityBy Tom LydonJune 15, 2021
Disruptive Technology ChannelPandemic Opening the Door for Widespread Genetic TestingBy Tom LydonJune 2, 2021
Disruptive Technology ChannelA Base Hit: How Base Editing Is Changing GenomicsBy Tom LydonMay 26, 2021
Disruptive Technology ChannelHow Genomics Is Improving Cancer Screening, InvestingBy Tom LydonMay 18, 2021
Disruptive Technology ChannelIs This Ark Invest ETF a Sustainable Investing Play?By Tom LydonMay 13, 2021
Disruptive Technology ChannelAccelerating Gene Therapies? There’s an ETF for ThatBy Tom LydonMay 5, 2021
Disruptive Technology ChannelLong Read Sequencing Is Securing a Long Runway for ‘ARKG’By Tom LydonApril 27, 2021
Disruptive Technology ChannelCancer Detection Meets Portfolio Perfection: The ARKG ETFBy Tom LydonApril 13, 2021
Disruptive Technology ChannelHow ARKG’s Genomics Will Personalize Cancer TreatmentBy Tom LydonMarch 31, 2021
Disruptive Technology ChannelSynthetic Biology: What It Is and Why ‘ARKG’ Is So Levered to ItBy Tom LydonMarch 16, 2021
